

WHAT IS CLAIMED IS:

1. In a method of treating a condition in a host by administering an effective amount of a selective estrogen receptor modulator to the host to control and regulate estrogenic impact on specific tissues and organs, the improvement which comprises additionally administering an effective amount of an agent which exhibits progestogenic activity to the host.

2. The method of claim 1 wherein the selective estrogen receptor modulator is clomiphene.

3. The method of claim 1 wherein the selective estrogen receptor modulator is a benzothiophene.

4. The method of claim 1 wherein the additional agent is an antiprogesterin *which exhibits progestogenic*

5. The method of claim 4 wherein the antiprogesterin is a progesterone receptor antagonist.

6. The method of claim 5 wherein the selective estrogen receptor modulator is clomiphene.

7. The method of claim 5 wherein the selective estrogen receptor modulator is a benzothiophene.

8. The method of claim 4 wherein the amount of antiprogesterin is that sufficient to maintain the blood

estrogen concentration in the range of about 25 to 125 pg/ml.

9. The method of claim 8 wherein the amount of antiprogesterin is that sufficient to maintain the blood estrogen concentration in the range of about 60 to 90 pg/ml.

Sub AA2  
10. The method of claim 1 wherein the additional agent <sup>which exhibits progestogenic</sup> expresses both androgenic and progestogenic activity.

11. The method of claim 10 wherein the additional agent <sup>which exhibits progestogenic</sup> comprises the combination of an androgen and a progestin.

12. The method of claim 10 wherein the additional agent <sup>which exhibits progestogenic</sup> is a single material which expresses both activities.

13. The method of claim 12 wherein the additional agent <sup>which exhibits progestogenic</sup> is danazol or levonorgestrel.

Sub A21  
14. A kit comprising a plurality of tablets containing an effective amount of a selective estrogen receptor modulator and an effective amount of an agent which exhibits progestogenic activity.

15. The kit of claim 14 wherein the selective estrogen receptor modulator is clomiphene or a benzothiophene.

Sub  
2A3

~~15. The kit of claim 14 wherein the agent is  
an antiprogesterin.~~

~~which is not~~

17. The kit of claim 16 wherein the  
antiprogesterin is a progesterone receptor antagonist.

18. The kit of claim 14 wherein the agent  
expresses both androgenic and progestogenic activity.

19. The kit of claim 18 wherein the agent  
comprises the combination of an androgen and a progestin.

20. The kit of claim 18 wherein the agent is a  
single material which expresses both activities.

add  
c1